Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Forging Alliances Proves Successful for West Virginia Society

  |  

With only 15 practicing rheumatologists in the state, members of West Virginia’s Rheumatology (WVR) Society knew early on they needed a stronger voice to help their patients. So WVR Society President Suzanne Gharib, MD, joined West Virginia’s state medical society, comprising physicians from a range of specialties. “It turns out our state medical society was…

Affiliate Society Council Meeting Provides Motivation, Fellowship, Opportunity

  |  

On Wednesday, May 16, 2018, the ACR’s Affiliate Society Council (ASC) convened a meeting in Washington, D.C., in conjunction with the ACR’s Advocacy Leadership Conference. Despite inclement weather that delayed or cancelled numerous flights, several rheumatology representatives from states across the U.S. attended the meeting in person, while others participated by conference call. “It was…

HCV-Associated Cryoglobulinemic Vasculitis Resolves after Virologic Cure

Will Boggs MD  |  

NEW YORK (Reuters Health)—Cryoglobulinemic vasculitis associated with hepatitis C virus (HCV) infection resolves after effective treatment with direct-acting antivirals (DAAs), with most patients remaining in remission for two or more years, researchers from Spain report. “Most clinical manifestations of the disease improve over time, but some patients may have a clinical recurrence of their disease…

FDA Names Drugmakers Potentially Acting to Delay Cheap Generics

Michael Erman  |  

(Reuters)—The U.S. Food and Drug Administration on Thursday listed drugmakers, including Celgene Corp, Johnson & Johnson, Gilead Sciences and Novartis AG, who the regulator says are potentially blocking access to samples of their drugs to delay generic competition. Generic drugmakers may not be able to develop alternatives without access to samples of branded products they…

Romosozumab Has Biggest BMD Benefit in First Year of Treatment

Anne Harding  |  

NEW YORK (Reuters Health)—Romosozumab shows smaller benefits for increasing bone mineral density (BMD) in the second year of treatment compared to the first, new research suggests. The extension of a phase 2 study in postmenopausal women with low bone mass also found BMD decreased sharply when patients on romosozumab were switched to placebo after two…

ACR Program Encourages Innovation & Opportunity

  |  

With a steadily diversifying U.S. population, the professional and societal consequences of health disparities continue to grow. Rheumatologists may need to innovate to prevent these disparities for their patients. A new ACR program will focus on member-led projects that reduce health racial and ethnic disparities for patients with rheumatic disease…

Cutaneous Lupus Tied to Risk for Coexisting Autoimmune Conditions

Marilynn Larkin  |  

NEW YORK (Reuters Health)—Patients with cutaneous lupus erythematosus (CLE) should be monitored closely for other autoimmune conditions, researchers suggest. Dr. Benjamin Chong, Dr. Linda Hynan and Elaine Kunzler of the University of Texas Southwestern Medical Center in Dallas analyzed data from 129 adults in the UTSW Cutaneous Lupus Registry (mean age, 49; 79% women). Individuals…

Existing CT Scans as Good as DXA for Assessing Hip Fracture Risk

Scott Baltic  |  

NEW YORK (Reuters Health)—A “biomechanical” analysis of a previously taken pelvic or abdominal computed tomography (CT) scan is at least as accurate in assessing an individual’s hip fracture risk as a dual-energy X-ray absorptiometry (DXA) scan, according to new research. This accuracy of the hip bone mineral density (BMD) T-score as measured by the biomechanical…